Andrew Keezer
YOU?
Author Swipe
View article: Prediagnostic White Blood Cell DNA Methylation and Risk of Breast Cancer in the Prostate Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort
Prediagnostic White Blood Cell DNA Methylation and Risk of Breast Cancer in the Prostate Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort Open
Background: White blood cell (WBC) DNA may contain methylation patterns that are associated with subsequent breast cancer risk. Using a high-throughput array and samples collected, on average, 1.3 years prior to diagnosis, a case–cohort an…
View article: Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies Open
Next-generation sequencing has revealed recurring somatic mutations in Waldenström macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4 (30%-40%), ARID1A (17%), and CD79B (8%-15%). Deletions involving chromosome 6q are common in patien…
View article: Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas Open
Hematopoietic cell kinase (HCK) is an SRC family member that is aberrantly upregulated in B-cell neoplasms dependent on MYD88-activating mutations and supports their growth and survival. We showed herein that activation of Toll-like recept…
View article: Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia
Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia Open
Rituximab‐containing regimens are commonly used for frontline therapy in patients with symptomatic Waldenström macroglobulinemia (WM). We had observed that a portion of WM patients experienced deepening of response months to years after th…
View article: CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia
CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia Open
Key Points CXCR4 S338X clonality ≥25% is associated with lower very good partial response and shorter progression-free survival to ibrutinib. CXCR4 S338X clonality assessment represents a novel biomarker to predict outcomes to ibrutinib in…
View article: <i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib
<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib Open
Summary Ibrutinib is associated with response rate of 90% and median progression‐free survival (PFS) in excess of 5 years in Waldenström macroglobulinaemia (WM) patients. CXCR4 mutations are detected in 30–40% of patients with WM and assoc…
View article: PF485 PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION‐FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB
PF485 PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION‐FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB Open
Background: Ibrutinib is approved in Europe and the US for the treatment of Waldenstrom macroglobulinemia (WM) with a median progression‐free survival (PFS) measured on several years. As PFS is commonly used for drug approval by regulatory…